Karen L. Smith, Global Head of R&D and CMO at Jazz Pharmaceuticals plc (JAZZ), bought 1,160 shares at $143.63 ($167K) on 2016-07-13, disclosed to the SEC on 2016-07-13.
Open-market purchase of $167k JAZZ by Global Head of R&D and CMO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $143.63 | 580 | $83K | 50.0% |
| 2 | $143.63 | 580 | $83K | 50.0% |
| Total | $143.63 avg | 1,160 | $167K | 100% |
| Filing → |
| XLRN | SELL | 2021-04-02 | $2.4M | — | Filing → |
| JAZZ | BUY | 2016-08-12 | $167K | — | Filing → |
| JAZZ | BUY | 2016-06-15 | $167K | — | Filing → |